Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017136453) NRF2 ACTIVATING COMPOUNDS AND USES THEREOF
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/136453 International Application No.: PCT/US2017/016069
Publication Date: 10.08.2017 International Filing Date: 01.02.2017
IPC:
C07D 401/14 (2006.01) ,C07D 401/04 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
Applicants:
RIGEL PHARMACEUTICALS, INC. [US/US]; 1180 Veterans Boulevard South San Francisco, CA 94080, US
Inventors:
DUNCTON, Matthew; US
SINGH, Rajinder; US
Agent:
NG, Rudy; US
Priority Data:
62/290,85303.02.2016US
Title (EN) NRF2 ACTIVATING COMPOUNDS AND USES THEREOF
(FR) COMPOSÉS ACTIVATEURS DE NRF2 ET LEURS UTILISATIONS
Abstract:
(EN) Aspects of the present disclosure include compounds that activate Nrf2. Such compounds may find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
(FR) Des aspects de la présente invention comprennent des composés qui activent Nrf2. De tels composés peuvent être utiles dans le traitement de maladies et troubles auto-immuns et inflammatoires tels que, par exemple, le psoriasis et la sclérose en plaques. Des modes de réalisation de la présente invention concernent en outre des compositions pharmaceutiques qui comprennent ces composés, des procédés d’utilisation de ces composés dans le traitement de différents maladies et troubles, des procédés de préparation de ces composés et des intermédiaires utiles dans ces procédés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CA3012702CN108699034EP3411368